Diabetic remission rate
Time frame · 3 and 12 months after discontinuation of medication
Diabetic remission rate at 3 and 12 months after discontinuation of medication and the time of diabetic remission
Time required to achieve glycemic goal
Time frame · 6 months of medication
The time required to achieve glycemic goal(FBG \<6.1mmol/L, 2h PPG \<8.0mmol/L or HbA1c#6.5%)
EQ-5D-5L questionnaires, quality of life
Time frame · At baseline, at 6 months of medication treatment, and at 3, 6, and 12 months after discontinuation of medication
EQ-5D-5L questionnaires, assessment of quality of life. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
Incremental cost per additional remission
Time frame · 6 months after discontinuation of medication
Incremental cost per additional remission at 6 months after discontinuation of medication
HbA1c
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
HbA1c level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Blood glucose level
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Fasting and 2-hour postprandial blood glucose level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Blood insulin level
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Fasting and 2-hour postprandial insulin level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Blood C-peptide level
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Fasting and 2-hour postprandial C-peptide level at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Pancreatic β-cell function
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
HOMA-B at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
Insulin resistance
Time frame · At baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication
HOMA-IR at baseline, at 6 months of medication, and at 3, 6, and 12 months after discontinuation of medication